chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Right thigh edematous and erythematous (splotchy) warm to touch (+) firm.  Right thigh 14.5 inch, left thigh 12.5inch.
Pt recv vax on unspecified day; post vax pt exp macular papular rash, fever (103 x 3 days), irritable, less sleeping x 5 days, crying
This spontaneous report was received from a healthcare worker via a company representative and refers to a 20 year old female patient. The patient's concurrent conditions included anxiety. The patient's concomitant medications included an unspecified anxiety medication. She did not have any drug reactions or allergies. On an unknown date, the patient was vaccinated with the first dose of GARDASIL 9 (exact dose, anatomical location, lot # and expiration date were not reported, intramuscularly) and at that time, the patient had no adverse event to report. On 02-AUG-2016, the patient was vaccinated with the second dose of GARDASIL 9 (lot # M003659, expiration date 20-SEP-2017) and she fainted after the dose was administered. The patient received a treatment for the adverse event. There was no laboratory tests performed. The outcome of fainting was reported as recovered on the same day. The relatedness between the event of GARDASIL 9 was not reported. Additional information has been requested.
I still have COVID-19 right now. It started with a lot of sneezing, coughing, sweating, hot and cold chills. I took a COVID-19 test at home, which was positive. I had an awful headache. Today is the 3rd or 4th day, and I am still sweating and coughing. Stuffy nose and congestion, mild fever today. I stopped sneezing, though. I am taking TYLENOL.
A 22 year old received her flu shot between 0600 and 0800 hrs on Friday, 1/9/04. Pt worked 4 hrs following the shot then, because she wasn't feeling well and had a fever, went home. She saw her to the doctor on Monday, 1/12/04, as she wasn't feeling well. Pt died on Wednesday, 1/21/04. The pt's husband, relayed that his wife was being treated for hypertension and diabetes. He added that when she saw her doctor on 1/12, that he was concerned about her blood pressure. The husband also said that she was coughing and had a hard time breathing when she was laying down. The ER record received on 3/8/04 states cyanosis and pale.  Chills, sweats, fatigue, unresponsive.  Nurse follow up on 06/18/04 states: "Add: Acute Bronchial Pneumonia."
This medically confirmed spontaneous report (initial receipt 28-OCT-2014) concerns a 28 year old male patient. On 26-OCT-2014, AFLURIA underwent temperature excursion at 50 degree Fahrenheit. On 27-OCT-2014, AFLURIA again had temperature excursion AFLURIA (batch number: T50507) via intramuscular route at 0.5 ml. Outcome was reported as unknown. Reporter's comments: The reporter assessed the event as non-serious.
Chills, severe headache and body aches, fatigue. Symptoms began about 11 hours after administration of the vaccine and last about 12 hours from onset. Injection site soreness lasted approximately 4 days.
Myalgia Narrative:  Approx 6 hrs after vax, had body aches all over. Took two doses of Tylenol 600mg. Fatigued. Slept most of 3/13/2017. No other symptoms. Felt normal 3/14/21.  Other Relevant History:
1st dose of Shingrix on 11Sep2019 / 2nd dose on 06Apr2021; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 73-year-old female patient who received Herpes zoster (Shingrix) (batch number 9NH54, expiry date 14th October 2022) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 11th September 2019).   On 6th April 2021, the patient received the 2nd dose of Shingrix. On 6th April 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were provided as follows: The reporter stated that, the patient received 2nd dose late than the recommended schedule which led to lenghtening of vaccination schedule. No symptoms reported. The reporter consented to follow up.
patient had fatigue and a red hot injection site few hours after first dose; patient had fatigue and a red hot injection site few hours after first dose; patient had fatigue and a red hot injection site few hours after first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INJECTION SITE WARMTH (patient had fatigue and a red hot injection site few hours after first dose), FATIGUE (patient had fatigue and a red hot injection site few hours after first dose) and INJECTION SITE ERYTHEMA (patient had fatigue and a red hot injection site few hours after first dose) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included PRAVASTATIN and LAMOTRIGINE (LAMICTAL) for an unknown indication.    On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jan-2021, the patient experienced INJECTION SITE WARMTH (patient had fatigue and a red hot injection site few hours after first dose), FATIGUE (patient had fatigue and a red hot injection site few hours after first dose) and INJECTION SITE ERYTHEMA (patient had fatigue and a red hot injection site few hours after first dose). The patient was treated with ASPIRIN [ACETYLSALICYLIC ACID] for Adverse event, at an unspecified dose and frequency and PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, INJECTION SITE WARMTH (patient had fatigue and a red hot injection site few hours after first dose), FATIGUE (patient had fatigue and a red hot injection site few hours after first dose) and INJECTION SITE ERYTHEMA (patient had fatigue and a red hot injection site few hours after first dose) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-356141, MOD-2021-356002 (Patient Link).
Fever to 103 degrees F beginning 4-6 hours after receiving dose of FLUZONE. Also c/o HA, decreased appetite, body aches. Physical exam unremarkable.
Arm soreness on day of injection which went away by the next morning. 8 days after initial injection,  woke up with redness, pain, and a hard lump that also itches at the injection site.
Soreness, shivering/shaking and fever of nearly 103 degrees began around 7:30 pm , followed by significant sweating.
Information has been received from a licensed practical nurse concerning a patient (age and gender unknown), who, on an unspecified date, was vaccinated with a dose of Gardasil (Lot# 658556/1060U).  Subsequently, the patient experienced pain in arm and trouble lifting the arm.  At the time of the report, the outcome of the patient was unknown.  This is one of two reports from the same source.  Additional information has been requested. Initial and follow-up information has been received from a physician and a certified medical assistant concernign a 71 year old female with an allergy to PERCOCET, who on 28-NOV-2007 and 19-FEB-2008 was vaccinated with a first and second dose of HPV vaccine (lot# 658556/106oU), respectively. The physician reported that on 19-FEB-2008 the patient experienced mild pain of the entire left arm, and severe pain at the injection site. The patient used MOTRIN intermittently and was offered physical therapy, which the patient decline. The certified medical assistant reported that on "13-APR-2008" the patient experienced pain in the arm, slight weakness, and left shoulder pain. The patient recovered from severe arm pain at the injection site, and mild pain of the entire left arm in April 2008 and the outcome for pain in arm, slight weakness, and left shoulderpain were not reported. The medical assistant considered the left shoulder pain, arm pain, and slight weakness to be disabling. This is an amended report.The physician was made to be the primary reporter. This is one of two reports from the same source. Additional information is not expected.
48hr p/vax pt devel axillary lymphadenitis in the same arm;rx po keflex;
BRAZO, HOMBRO, TOBILLO, PECHO, CUELLO, PARTE DE DONDE LA CABEZA SE JUNTA CON EL CUELLO UN DOLOR COMO CUANDO LE PONEN LAS INJECCIONES DE VITAMINAS.  HE PERDIDO LA FUERZA. NO HE PERDIDO SENSIBILIDAD PERO NO HAY FUERZA MUSCULAR.  CUANDO VIRO EL CUELLO ME DUELE. EL PIE SE HA MEJORADO, PERO EL TRONCO DEL MULO ME DUELE.  EL PECHO ME DUELE CUANDO TOSO. NO TENGO NINGUNA FUERZA NI MOBILIDAD EN MI BRAZO IZQUIERDO Y UN DOLOR "CANSADO" EN EL CUELLO.
"Symptoms common to pneumonia"-barely able to breathe, tightness in lungs, nose running constantly, gurgling in lungs, achingly tired, mucus, severely bloated.
Case number PHEH2015US020513, is an initial spontaneous report from a pharmacist via medical information received 09 Oct 2015. This report refers to an adult female patient. Medical history and concomitant medications were not reported. The patient was vaccinated with FLUCELVAX (batch number: 174271, expiry date: May 2016) on an unknown date. On 06 Oct 2015 the patient presented with acute reaction of hives, nausea and feeling flushed. The outcome, seriousness and causality of the events were not reported. Seriousness assessment of "hives, nausea and feeling flushed" was upgraded based on information in the source document.
weakness; aches; generalized fatigue; This spontaneous case was reported by a patient and describes the occurrence of ASTHENIA (weakness), MYALGIA (aches) and FATIGUE (generalized fatigue) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced ASTHENIA (weakness), MYALGIA (aches) and FATIGUE (generalized fatigue). At the time of the report, ASTHENIA (weakness), MYALGIA (aches) and FATIGUE (generalized fatigue) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medication were reported. Treatment medication was not provided.
Warmth, pink, slight swelling below injection site. Mother gave several doses of TYLENOL the first 48 hours after immunization.  The next evening she noted a discolored (described as "dusky") area at the same site.  Denies injury, tenderness, swelling had gone away." Dusky discoloration" remained.  Mother notified 08/11/2006.  As of 08/14/2006 area had lightened in color.  Hasn't notified family physician. Area about the size of golf ball diameter.
Nursing home requested vaccination for patient and patient signed consent.  Upon entering Pfizer first dose vaccine in links discovered patient had previously receieved a Janseen vaccine on 06/01/2021.  No adverse event occured while monitoring patient after pfizer vaccine was administered.
Apnoea within hours of vaccine administration. Seen in ER and had severe apnoeic event during lab draw. Airlifted to medical center (referral center). Hospitalized x 2 days.
Pt rec'd DTP/OPV 14MAY91; On 15MAY91 @ 4AM awoke disoriented, slept a lot, & did not eat or drink for 28hrs; Sl swelling & redness @ inject site; Seen by MD dx vaccine rxn & placed on Promethazine;
experienced some fatigue after the first injection; This is a spontaneous report from a contactable consumer or other non hcp (patient's mother) Pfizer sponsored program.  A 12-years-old male patient received BNT162B2, (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: was not reported) via an unspecified route of administration on an unspecified date as 1st dose, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced some mild fatigue after the first injection on an unspecified date. The reporter wanted to know why the Pfizer covid-19 vaccine dose was being used in kids only 10 mcg while the dose used in 1215-year-old is the same as the adult dose, 30 mcg. The outcome of the event was unknown.   No further information was provided or obtained.
Rash appeared at the injection site on my left upper arm (deltoid); The rash is risen, red and yellow - looks sort of like a huge allergic reaction to a mosquito bite; It?s a bit itchy but not as itchy as a mosquito bite
PATIENT REPORTS APPROXIMATELY 4 HOURS AFTER RECEIVING VACCINE - STARTED FEELING FUNNY. COULDN'T STAND UP, RAISE ARM, COMMUNICATE WITH FAMILY. FAMILY CALLED FOR AMBULANCE TO TRANSPORT TO HOSPITAL. PATIENT STATES SHE WAS UNAWARE OF HER SURROUNDINGS. NON-CONCLUSIVE RESULTS REPORTED.
Patient  came in to receive his first Moderna Covid vaccination around 4pm 09/27/2021.  After a few minutes post vaccination, patient appeared to be sweating and stated his chest hurt slightly.   He appeared to be hyperventilating slightly and not taking full breaths.  He began to hunch over and began to make moaning/crying noises.  911 called and paramedics arrived.  Patient was taken to hospital upon patients request.
Moderna COVID-19 Vaccine EUA  Severe chills lasting 1 hour 2.5 days after injection accompanied by high fever (peaking at 103deg) and sore throat lasting 3 days.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. On 18-SEP-2013 the patient was self vaccinated with one dose of ZOSTAVAX (lot # not reported) in her stomach via the subcutaneous route. No adverse effect reported. It was unspecified if the patient had sought medical attention. Additional information has been requested.
Patient on 4/18/21 experienced "chicken wire" vision (never before an issue), after vision issues patient said he lost vision on and off for the next 24 hours, accompanied with mental confusion, and was unable to get out of bed on the morning of 4/19/21.   Next two days a continued decline in in ability to ambulate and demonstrated neurological deficits on 4/20/21 of impaired vision, cognition and experienced difficulty in moving limbs.   Patient was in a car accident on 4/21/21, is now hospitalized, unable to ambulate, and has further neurological deficits with impaired speech, cognition, and movement as well as pneumonia.
Fever; Swollen lymph nodes; Chills; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EL8982 and expiry date were not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported.  On an unspecified date, the patient experienced fever, swollen lymph nodes and chills. Clinical outcome of the events was unknown.  Follow-up attempts are completed. No further information is expected.
she can't function at all; unbelievably dizzy; This spontaneous case was reported by a patient and describes the occurrence of LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (she can't function at all) and DIZZINESS (unbelievably dizzy) in an 88-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 010H22A) for COVID-19 vaccination.     Patient never had COVID positive test or diagnosis. Patient had no history relating to mentioned adverse events and both Acute and Chronic illnesses at the time of vaccination.  Previously administered products included for Product used for unknown indication: flu vaccine (given within 1 month prior to Moderna COVID-19 vaccine) in 2022. Past adverse reactions to the above products included No adverse event with flu vaccine. Concurrent medical conditions included Sulfonamide allergy (Sulfas).    On 15-Nov-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Nov-2022, the patient experienced LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (she can't function at all) and DIZZINESS (unbelievably dizzy). At the time of the report, LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (she can't function at all) and DIZZINESS (unbelievably dizzy) had not resolved.            No concomitant drug was reported. Patient received first dose on 06-Feb-2021, second dose on 06-Mar-2021, first booster dose on 30-Nov-2021, second booster on 13-May-2022 no lot number recorded for previous four doses. The patient has not experienced a similar event in the past. It was reported that patient did not seek medical care. No treatment drug was reported.
This spontaneous report as received from a medical assistant refers to a 17 year old patient of unknown gender. The patient's drug allergies and pertinent medical history was not reported. On 20-JUN-2014 the patient was vaccinated with third dose of GARDASIL (dose, frequency and route of administration were not reported) (lot # H020002, expiry date: 08-AUG-2015) and first dose of VAQTA (dose, frequency and route of administration were not reported) (lot # J005010, expiry date: 23-OCT-2015) for prophylaxis which were stored improperly. No adverse effects were noted. No product quality complaint was reported for GARDASIL and VAQTA. This case linked to 1407USA012902, 1407USA012903, 1407USA012904, 1407USA012905, 1407USA012906, 1407USA012907, 1407USA012908, 1407USA012909, 1407USA012910, 1407USA012911, 1407USA012912, 1407USA012913, 1407USA012914, 1407USA012915, 1407USA012916, 1407USA012917, 1407USA012918, 1407USA012919, 1407USA012920, 1407USA012921, 1407USA012922, 1407USA012923, 1407USA012924, 1407USA012925, 1407USA012926, 1407USA012927, 1407USA012928, 1407USA012929, 1407USA012930, 1407USA012931, 1407USA012932, 1407USA012933, 1407USA012934, 1407USA012935, 1407USA012936, 1407USA012937, 1407USA012938, 1407USA012939, 1407USA012940, 1407USA012941, 1407USA012942, 1407USA012943, 1407USA012944, 1407USA012945, 1407USA012946, 1407USA012947, 1407USA012948, 1407USA012949, 1407USA012950, 1407USA012951, 1407USA012952, 1407USA012953, 1407USA012954, 1407USA012955, 1407USA012956, 1407USA012957, 1407USA012958, 1407USA012959, 1407USA012960, 1407USA012961, 1407USA012962, 1407USA012963, 1407USA012964, 1407USA012965, 1407USA012966, 1407USA012967, 1407USA012968, 1407USA012969, 1407USA012970, 1407USA012971, 1407USA012972, 1407USA012973, 1407USA012974, 1407USA012975, 1407USA012076, 1407USA012977, 1407USA012978, 1407USA012979, 1407USA012980, 1407UISA012981, 1407ISA012982, 1407USA012983, 1407USA012984, 1407USA012985, 1407USA012986, 1407USA012987, 1407USA012988, 1407USA02989, 1407USA012990, 1407USA012991, 1407USA012999, 1407USA013000, 1407USA013013 and 1407USA013014 (same reporter link). Additional information has been requested.
VR developed perioral tingling and nausea appx 15 minutes after injection. BP: 140/90, HR 70, SP02 >94%. Symptoms resolved after appx. 10 minutes.  The VR declined EMS services.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Nov2022 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm, as dose 4 (booster), single (Batch/Lot number: unknown), in left leg and as dose 5 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation; bnt162b2 (BNT162B2), in Apr2022 as dose 1, single (Batch/Lot number: unknown), in left arm and in Jun2022 as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "No" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid from 14Oct2023 to 18Oct2023. Clinical course: After 4 days of finishing treatment with Paxlovid and testing negative for Covid 19, patient got Covid rebound, had covid symptoms and tested positive.  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5, bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300336301 same reporter/patient with different drug/AE;
Right arm red, sore, warm to touch.  Went to ER. Diagnosed Celluclitis.  Prescribed Keflex.
About 2 days after the vaccination I began to have chest pain that would not go away unless I leaned forward. It hurt all the time for about 7 days and went away gradually. I believe it to me myocarditis. As well as the above reaction, my migraine frequency went up noticeably from around 10 days a month to 15 or 20. This has not shown any sign of abating and seems to be permanent. Please note that the heart issue went away but the migraine problem definitely has not.
immediately after the injection was administered, pt experienced a vagal response; experienced instant lightheadedness, dizziness, and diaphoresis. after elevating feet and sipping cool water, all symptoms resolved after about 15 minutes and pt was able to leave the clinic on her own. pt also reported high level of anxiety prior to receiving injection.